NASDAQ:ETNB 89bio (ETNB) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free ETNB Stock Alerts $9.22 +0.36 (+4.06%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$8.90▼$9.3550-Day Range$8.25▼$13.7752-Week Range$6.57▼$22.93Volume645,965 shsAverage Volume730,594 shsMarket Capitalization$877.93 millionP/E RatioN/ADividend YieldN/APrice Target$29.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get 89bio alerts: Email Address 89bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside214.5% Upside$29.00 Price TargetShort InterestBearish11.77% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.16Based on 3 Articles This WeekInsider TradingAcquiring Shares$20.72 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.20) to ($2.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.47 out of 5 starsMedical Sector2815th out of 5,424 stocksPharmaceutical Preparations Industry1249th out of 2,550 stocks 4.4 Analyst's Opinion Consensus Rating89bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst Coverage89bio has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.77% of the outstanding shares of 89bio have been sold short.Short Interest Ratio / Days to Cover89bio has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in 89bio has recently decreased by 2.94%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend Yield89bio does not currently pay a dividend.Dividend Growth89bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ETNB. Previous Next 2.3 News and Social Media Coverage News Sentiment89bio has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for 89bio this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ETNB on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added 89bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 89bio insiders have bought 42,916.84% more of their company's stock than they have sold. Specifically, they have bought $20,722,500.00 in company stock and sold $48,173.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of 89bio is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for 89bio are expected to decrease in the coming year, from ($2.20) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 89bio is -4.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 89bio is -4.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio89bio has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Allegiance GoldCould Your Accounts Be Frozen?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit About 89bio Stock (NASDAQ:ETNB)89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Read More ETNB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ETNB Stock News HeadlinesMay 2, 2024 | finance.yahoo.com89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASHMay 2, 2024 | globenewswire.com89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASHMay 4, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 26, 2024 | americanbankingnews.com89bio, Inc. (NASDAQ:ETNB) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 24, 2024 | investing.comBofA raises 89bio to stock buy amid MASH outlookApril 22, 2024 | finance.yahoo.com89bio, Inc. (ETNB) Stock Historical Prices & Data - Yahoo FinanceApril 17, 2024 | globenewswire.com89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of DirectorsApril 5, 2024 | globenewswire.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 4, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 3, 2024 | finance.yahoo.com89bio Inc CEO Rohan Palekar Sells 52,718 SharesMarch 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for 89bio’s Pegozafermin: A Promising NASH Treatment with Strong Regulatory EndorsementsMarch 27, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Perspective Therapeutics (CATX)March 27, 2024 | globenewswire.com89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated CirrhosisMarch 16, 2024 | finance.yahoo.comETNB Apr 2024 12.500 putMarch 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Intuitive Surgical (ISRG)March 12, 2024 | globenewswire.com89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with FibrosisMarch 10, 2024 | 247wallst.comBuffett Loads Up on This Stock Again, Plus CEO Insider BuyingMarch 8, 2024 | globenewswire.com89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 7, 2024 | msn.comInsider Trading: Director Boosts Stake in 89bio (NASDAQ:ETNB) StockMarch 7, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for 89bio with Potential Market Edge in Fibrosis and Metabolic DiseasesMarch 6, 2024 | realmoney.thestreet.com89bio price target raised by $8 at Evercore ISI, here's whyMarch 5, 2024 | globenewswire.com89bio to Participate in the Leerink Partners Global Biopharma ConferenceMarch 5, 2024 | wsj.com89bio Inc.March 5, 2024 | finance.yahoo.comETNB Mar 2024 20.000 putMarch 5, 2024 | finance.yahoo.comETNB Mar 2024 20.000 callMarch 2, 2024 | finance.yahoo.com89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ...February 29, 2024 | globenewswire.com89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdatesSee More Headlines Receive ETNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ETNB CUSIPN/A CIK1785173 Webwww.89bio.com Phone415-432-9270FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Stock Price Target$29.00 High Stock Price Target$37.00 Low Stock Price Target$14.00 Potential Upside/Downside+214.5%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-142,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-31.01% Return on Assets-27.84% Debt Debt-to-Equity Ratio0.05 Current Ratio20.04 Quick Ratio20.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.75 per share Price / Book1.60Miscellaneous Outstanding Shares95,220,000Free Float91,035,000Market Cap$877.93 million OptionableOptionable Beta1.15 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Rohan Palekar (Age 58)CEO & Director Comp: $990.52kMr. Quoc Le-Nguyen (Age 56)Chief Technical Operations Officer & Head of Quality Comp: $654.44kDr. Harry Mansbach M.D. (Age 59)Chief Medical Officer Comp: $691.87kMr. Ryan Stephen Martins (Age 45)Chief Financial Officer Mr. Shiva K. Natarajan CPA (Age 58)Senior Vice President of Finance & Principal Accounting Officer Ms. Annie J. Chang M.B.A.VP of Investor Relations & Corporate CommunicationsMs. Amanda KuriharaVice President of People & CultureMs. Yun Bai Ph.D.VP and Head of Chemistry, Manufacturing & Controls ( CMC )Ms. Melissa AbelSenior Vice President of Commercial StrategyMr. Paul ShinSenior Vice President of R&D OperationsMore ExecutivesKey CompetitorsEnliven TherapeuticsNASDAQ:ELVNArcutis BiotherapeuticsNASDAQ:ARQTTango TherapeuticsNASDAQ:TNGXIntercept PharmaceuticalsNASDAQ:ICPTZentalis PharmaceuticalsNASDAQ:ZNTLView All CompetitorsInsiders & InstitutionsCapstone Investment Advisors LLCBought 103,767 shares on 5/1/2024Ownership: 0.109%Mirae Asset Global Investments Co. Ltd.Sold 28,920 shares on 5/1/2024Ownership: 0.018%China Universal Asset Management Co. Ltd.Bought 9,153 shares on 4/29/2024Ownership: 0.019%Principal Financial Group Inc.Bought 10,614 shares on 4/29/2024Ownership: 0.011%Wetzel Investment Advisors Inc.Bought 2,000 shares on 4/23/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions ETNB Stock Analysis - Frequently Asked Questions Should I buy or sell 89bio stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ETNB shares. View ETNB analyst ratings or view top-rated stocks. What is 89bio's stock price target for 2024? 7 brokerages have issued 12-month price objectives for 89bio's stock. Their ETNB share price targets range from $14.00 to $37.00. On average, they predict the company's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 214.5% from the stock's current price. View analysts price targets for ETNB or view top-rated stocks among Wall Street analysts. How have ETNB shares performed in 2024? 89bio's stock was trading at $11.17 on January 1st, 2024. Since then, ETNB stock has decreased by 17.5% and is now trading at $9.22. View the best growth stocks for 2024 here. How were 89bio's earnings last quarter? 89bio, Inc. (NASDAQ:ETNB) issued its quarterly earnings results on Thursday, February, 29th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.01. What ETF holds 89bio's stock? AdvisorShares Dorsey Wright Micro-Cap ETF holds 2,900 shares of ETNB stock, representing 0.92% of its portfolio. What other stocks do shareholders of 89bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), RTX (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO). When did 89bio IPO? 89bio (ETNB) raised $70 million in an initial public offering on the week of November 11th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager. Who are 89bio's major shareholders? 89bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Raymond James Financial Services Advisors Inc. (0.12%), Capstone Investment Advisors LLC (0.11%), Bourgeon Capital Management LLC (0.04%), China Universal Asset Management Co. Ltd. (0.02%), Mirae Asset Global Investments Co. Ltd. (0.02%) and Principal Financial Group Inc. (0.01%). Insiders that own company stock include Edward Morrow Atkinson III, Kathleen Laporte, Michael R Hayden, Ollin B Sykes, Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins. View institutional ownership trends. How do I buy shares of 89bio? Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ETNB) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.